Veillon-Berteloot Chantal
Known title: EVP & CHROCIK: 0001990905
Associated companies
Transaction History
| IART | ▼ Sell | Tax Withholding | 1,455 | $24K | 9/1/2026 | View on chart |
| IART | ▼ Sell | Tax Withholding | 5,420 | $52K | 3/11/2026 | View on chart |
| IART | ▼ Sell | Tax Withholding | 2,139 | $32K | 9/1/2025 | View on chart |
| IART | ▼ Sell | Tax Withholding | 1,412 | $21K | 9/1/2025 | View on chart |
| IART | ▼ Sell | Tax Withholding | 524 | $13K | 3/11/2025 | View on chart |
| IART | ▲ Buy | Grant | 7,343 | $0 | 3/11/2025 | View on chart |
| IART | ▼ Sell | Tax Withholding | 1,412 | $29K | 9/1/2024 | View on chart |
| IART | ▲ Buy | Grant | 3,475 | $0 | 3/11/2024 | View on chart |
| IART | ▲ Buy | Grant | 8,283 | $0 | 3/11/2024 | View on chart |
| IART | ▲ Buy | Grant | 4,678 | $0 | 9/1/2023 | View on chart |
| IART | ▲ Buy | Grant | 9,355 | $0 | 9/1/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Integra Focuses on ENT Portfolio; Analyst Target Cut to $15
Integra LifeSciences will showcase its ENT and instrument lines and sponsor new clinical research presentations at the AAO‑HNSF 2026 meeting. A recent analyst review lowered the price target to $15, reflecting a more cautious outlook. The company’s focus on ENT products comes amid a broader discussion of healthcare stocks that are of concern to investors.
Integra Focuses on ENT Portfolio; Analyst Target Cut to $15. Integra LifeSciences will showcase its ENT and instrument lines and sponsor new clinical research presentations at the AAO‑HNSF 2026 meeting. A recent analyst review lowered the price target to $15, reflecting a more cautious outlook. The company’s focus on ENT products comes amid a broader discussion of healthcare stocks that are of concern to investors.